Xtant Medical’s second-quarter sales reached $35.4 million, according to financial results posted Aug. 12.
Five notes:
1. Revenue grew 18% year over year, according to a news release.
2. The company saw net income of $3.6 million compared to a net loss of $3.9 million in the same time in 2024.
3. Highlights of the second quarter include plans to sell two spine implant lines to Companion Spine for about $19.2 million and the launch of OsteoFactor Pro.
4. Operating expenses decreased compared to the same period in 2024. Second-quarter expenses were $19.7 million in 2025 compared to $21.5 million in 2024.
5. Xtant Medical raised its 2025 guidance and expects full-year revenue to reach $131 million to $135 million.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
